1 / 5

Smoking Cessation in Smokers Motivated to Quit

STRATUS-US Trial. Smoking Cessation in Smokers Motivated to Quit . Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Robert Anthenelli . STRATUS-US Trial. 787 patients who smoked ≥10 cigarettes/day for at least 2 months and were motivated to stop smoking

thane
Download Presentation

Smoking Cessation in Smokers Motivated to Quit

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. STRATUS-US Trial Smoking Cessation in SmokersMotivated to Quit Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Robert Anthenelli

  2. STRATUS-US Trial 787 patients who smoked ≥10 cigarettes/day for at least 2 months and were motivated to stop smoking Randomized, double-blind, multicenter • Rimonabant • A selective cannabinoid type 1 receptor antagonist • 20 mg • n=261 • Rimonabant • A selective cannabinoid type 1 receptor antagonist • 5 mg • n=262 • Placebo • n=261 Treatment for 1 Year • Endpoints (1 year): • Smoking abstinence • Change in body weight in patients who stopped smoking Presented at ACC Scientific Sessions 2004

  3. STRATUS-US Trial Smoking abstinence at 7-10 weeks p < 0.001 for high-dose vs placebo p = NS for low-dose vs placebo Smoking abstinence at end of study p < 0.001 for high-dose vs placebo p = NS for low-dose vs placebo Presented at ACC Scientific Sessions 2004

  4. STRATUS-US Trial Change in weight from baseline among patients with a prolonged abstinence from smoking p<0.001 for rimonabant 20 mg vs placebo • Among patients with a prolonged abstinence from smoking, change in weight from baseline was significantly  in high-dose group compared with placebo (Figure) • In subgroup of patients who were overweight initially, BMI was significantly  in high-dose group versus placebo (-0.1 vs. 1.7, p<0.001) kg Presented at ACC Scientific Sessions 2004

  5. STRATUS-US Trial • Among patients smoking ≥10 cigarettes per day and motivated to stop smoking, use of the selective cannabinoid type 1 receptor antagonist rimonabant in a 20 mg dose was associated with an increase in prolonged smoking abstinence compared with placebo, but there was no difference between the 5 mg dose of rimonabant and placebo • Additionally, weight gain, which can be a negative side effect of smoking cessation, was lower in patients who received rimonabant 20 mg, with benefit seen even in obese patients • Further evaluation warranted

More Related